AI-generated research brief — verify at source
Sucrose Solution Shows No Benefit Over Placebo for Oral Rehydration in Pediatric Gastroenteritis
A double-blind randomized controlled trial found that a single dose of concentrated sucrose solution did not improve the volume of oral rehydration solution consumed by children with gastroenteritis compared to placebo, with the sucrose group actually ingesting slightly less fluid than controls (84 mL vs 95 mL; mean difference −11 mL; 95% CI −26 to 4). The confidence interval spans both modest benefit and modest harm, confirming that any true effect, if present, is likely clinically negligible.
What Was Studied
Investigators examined whether administering a concentrated sucrose solution at triage could improve oral fluid intake in young children presenting to a pediatric emergency department with vomiting due to gastroenteritis. The rationale rested on the hypothesis that fasting-induced ketosis may worsen vomiting in this population, and that providing a rapidly absorbed carbohydrate source might interrupt that cycle and facilitate oral rehydration.
How It Was Studied
This was a double-blind randomized controlled trial conducted between 2022 and 2024 at a tertiary pediatric emergency department. Children aged 6 months to 7 years whose vomiting was most likely attributable to gastroenteritis were eligible for enrollment. Of 2,001 children screened, 240 (12.0%) met eligibility criteria and were enrolled, with 208 (92%) contributing primary outcome data. Participants received either a single dose of concentrated sucrose solution (1.5 mL/kg, 3.5 g sucrose per 10 mL) or a diluted juice placebo (0.5 g sucrose per 10 mL), both followed by standardized oral rehydration therapy. The primary outcome was the total volume of oral rehydration solution ingested within the first two hours after the intervention.
What Was Observed
- Oral rehydration fluid intake did not differ meaningfully between groups: children in the sucrose arm consumed a mean of 84 mL compared with 95 mL in the placebo arm, a difference of −11 mL that did not reach statistical significance and whose confidence interval ranged from −26 to 4 mL, encompassing zero effect.
- Vomiting frequency was virtually identical across both arms, with a mean of 0.46 episodes in the sucrose group and 0.47 in the placebo group, indicating no reduction in emetic episodes attributable to the intervention.
- Rates of intravenous rehydration were similar between the sucrose group and the placebo group (14% vs 12%), as were rates of return visits to the emergency department (5% vs 4%), suggesting no meaningful downstream clinical benefit from sucrose administration.
- Ondansetron use was high and comparable in both groups (70% vs 68%), reflecting the clinical reality that antiemetic rescue was frequently required regardless of sucrose supplementation, and further undermining the case for sucrose as a useful adjunct.
Why This Matters
Gastroenteritis is a frequent driver of pediatric emergency department visits, and optimizing oral rehydration remains a central clinical goal to reduce the need for intravenous fluids. This trial directly tests the fasting-ketosis hypothesis as a mechanistic rationale for sucrose supplementation, and the consistently null results across all primary and secondary outcomes suggest that correcting putative carbohydrate deficit does not translate into improved tolerance of oral fluids or reduced clinical burden in this setting. The findings indicate that sucrose supplementation does not add meaningful value beyond standard oral rehydration therapy for this population.
How to Read This Result
Although this is a well-designed double-blind RCT with a clear null result across all outcomes, the enrollment of only 12% of screened children limits generalizability, and the single-dose design leaves open the possibility that repeated sucrose administration could produce a different effect.
Limitations
The abstract does not explicitly report study limitations.